The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis
Nathan Wong, PhD
Experts discuss the clinical and economic burden of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis in the US, exploring their impact on health care systems, the importance of prevention in reducing this burden, and the challenges of implementing preventive strategies, while considering the potential benefits of improved risk assessment and prevention in the ASCVD space.
Video content above is prompted by the following:
- Please describe the clinical and economic burden of atherosclerotic cardiovascular disease—or ASCVD—and aortic stenosis in the US today.
- How do these diseases impact health systems like the ones you work with?
- What role does prevention play in mitigating this burden?
- Adherence to preventive regimens can be difficult for patients. On a population level, do the challenges of implementing preventive ASCVD strategies outweigh the benefits? Is there a place for better risk assessment and prevention in the ASCVD space?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
September 17th 2025
- BCMA-Targeted Bispecific Antibodies: Navigating the New Frontier of Myeloma
September 17th 2025
- Linvoseltamab: A New Horizon for Relapsed Myeloma
September 17th 2025
- Rapid Therapeutic Effects Seen With a JAK Inhibitor
September 17th 2025
- SALT Scoring for Alopecia Areata
September 17th 2025
- The Potential Role of Screening for Atrial Fibrillation
September 16th 2025